Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
AssigneeThe University of Chicago
InventorYang-Xin Fu
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
Claims22
A mutant LIGHT molecule with an amino acid sequence encoded by a nucleic acid sequence wherein the mutant LIGHT molecule
- i) binds to murine receptors of LIGHT with increased affinity as compared to wild type human LIGHT, and
- ii) binds to human receptors of LIGHT with at least the same affinity as compared to wild type human LIGHT.
8-23. (canceled)
25-27. (canceled)
A method of reducing the growth of primary tumor or cancer metastasis, the method comprising:
- (a) administering a pharmaceutical composition comprising a tumor-specific agent linked, conjugated or fused to a LIGHT polypeptide mutant or fragment, wherein the composition is sufficient to stimulate production of cytotoxic T lymphocytes;
- and (b) reducing the growth of primary tumor or cancer metastasis by stimulating activation of tumor-specific T-cells against the tumor.
39-41. (canceled)
Dependencies are inferred from the claim text.